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Abstract: Computed tomography angiography (CTA) detects signs of
large-vessel vasculitis (LVV) in about 67.5% of patients with giant-cell
arteritis (GCA) at the time of diagnosis and early aortic dilatation in
15%. The outcome of CTA-findings of LVV upon glucocorticoid
treatment has not been prospectively evaluated.
The aim of our study was to prospectively assess glucocorticoid-
induced changes in CTA findings of LVV in patients with GCA.
Forty biopsy-proven GCA patients evaluated by CTA atle´, MD, PhD, Mar MD, PhD,
Maria C. Cid, MD, PhD
were evaluated. Results were compared to those obtained at the time of
diagnosis.
CTA was repeated to 35 patients after a median follow-up of 13.5
months (IQ25–75% 12.4–15.8). Arterial wall thickening was still
present in 17 patients (68% of the patients who initially had LVV).
The number of affected segments and wall thickness at various aortic
segments significantly decreased and no patients developed new
lesions, new aortic dilation or increase in previous dilation. Contrast
enhancement disappeared in 15 (93.75%) of 16 patients in whom this
finding could be assessed.
Signs of LVV improve with treatment. While contrast enhance-
ment resolves in the majority of patients, vessel wall thickening
persists in two thirds. However, the number of affected aortic seg-
ments as well as aortic wall thickness significantly decreases. Longer
follow-up is necessary to determine the clinical significance of
persisting wall thickening and its relationship with relapses or sub-
sequent development of aortic dilatation or large-vessel stenoses.
(Medicine 94(5):e486)
Abbreviations: AA = abdominal aorta, ACEI = angiotensin
converting enzyme inhibitors, Ao = aortic, ARB = angiotensin II
receptor blockers, ATA = ascending thoracic aorta, CRP = C-
reactive protein, CTA = computed tomography angiography, DTA
= descending thoracic aorta, ESR = erythrocyte sedimentation rate,
FDG-PET = fluoro-deoxyglucose-possitron emission tomography,
Hb = hemoglobin, HU = Hounsfield units, IQ = interquartile, LVV
= large-vessel vasculitis, SD = standard deviation, SIR = systemic
inflammatory response, TA = thoracic aorta.
INTRODUCTION
G iant-cell arteritis (GCA) is a systemic granulomatousvasculitis affecting large- and medium-sized vessels.1–3
Although GCA was initially considered as a vasculitis mainly
involving the carotid and vertebral artery branches, prospective
imaging studies have recently demonstrated that widespread
large-vessel involvement is common.4–13
The prevalence of large-vessel inflammation in newly
diagnosed patients has been evaluated in a few prospective
studies only, using 18fluoro-deoxyglucose-positron emission
tomography (FDG-PET), computed tomography angiography
(CTA), or color duplex ultrasonography Frequency ranges from
29% to 74% of patients, depending on the vascular territoryique employed.4,6,8–12
olvement of the aorta has been evaluated
tive imaging studies using FDG-PET or
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computed tomography, with or without angiography,4,6,7 and
ranges from 45% to 65% of patients with GCA at the time of
diagnosis. Moreover, retrospective studies have shown that,
during follow-up, dilation of the aorta, particularly in the
thoracic segment, is significantly more frequent in GCA
patients than in the general population.14–17 Furthermore, a
cross-sectional systematic screening of 54 patients with GCA
demonstrated that aortic dilatation occurred in 12 (22.5%) after
a median follow-up of 5.4 years.18 An extended follow-up of
this cohort disclosed that 33.3% of patients develop aortic
dilatation after a median of 10.3 years.19 To date, the specific
mechanisms leading to aortic dilatation in GCA are unclear. It is
conceivable and assumed that aortic dilatation is a consequence
of previous inflammation but a direct link between initial
inflammation and subsequent dilatation has not been estab-
lished.
It has been hypothesized that aortic dilatation results from
persistent remaining subclinical aortic inflammation.20,21 How-
ever, surgical or necropsy specimens from aortic aneurysms,
usually obtained months or years after diagnosis, not always
disclose persistent inflammatory infiltrates or these are
residual.18–20 Consequently, early damage of the elastic fibers
and muscular layer by inflammation, inefficient vascular repair
or remodeling after injury, vascular ageing, and/or hemody-
namic factors may also contribute to aneurysm development,
regardless of whether or not active inflammation has
resolved.3,4,16,22,23
In this study, we prospectively evaluated the outcome
of CTA signs of large-vessel inflammation and remodeling
in GCA patients after approximately 1 year of glucocorticoid
treatment. Specific aims of our survey were (1) to investigate
Prieto-Gonza´lez et althe persistence or resolution of CTA findings suggesting
vascular inflammation (wall thickening and contrast enhance-
ment) compared to the initial evaluation,4 (2) to assess the
FIGURE 1. CTA of a newly diagnosed patient with GCA showing signifi
the late venous phase, sparing the intimal layer (panel B). Persistent a
enhancement in the late venous phase (panels C and D).
2 | www.md-journal.comdevelopment of signs of structural damage or remodeling
(dilation and/or stenosis), and (3) to identify clinical or blood
test data associated with resolution or persistence of CTA signs
of vascular inflammation.
PATIENTS AND METHODS
Patients
The initial cohort included 40 patients who had been
evaluated by CTA at the time of GCA diagnosis in order to
detect large-vessel involvement, as part of a prospective study.4
These patients were treated and followed by the investigators
according to a defined protocol and tapering schedule18,24–26
and were appointed a new CTA examination between 12–18
months after the initiation of glucocorticoid treatment. Two
patients were lost to follow-up (1 patient due to severe dementia
and 1 patient because of unknown reasons) and 3 declined a new
CTA. Follow-up CTA was completed in the remaining
35 patients.
Clinical and exploratory findings were prospectively
recorded at the time of diagnosis, and at 1, 3, 6, 9, 12
month-follow-up and at the time of CTA imaging. The recorded
items were: cranial symptoms (headache, scalp tenderness, and
jaw claudication), polymyalgia rheumatica, systemic symptoms
(weight loss, and fever), disease-related cranial ischemic com-
plications, and presence of extremity claudication. Acute phase
reactants including C-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), and hemoglobin were also determined at
every visit. A combination of clinical and blood test abnorm-
alities was used to evaluate the intensity of the systemic
Medicine  Volume 94, Number 5, February 2015inflammatory response (SIR) as previously reported.18 These
included fever >37 8C, weight loss >3 kg, hemoglobin (Hb)
<11 g/L, and erythrocyte sedimentation rate (ESR) 85mm/h.
cant aortic wall thickening (panel A) with contrast enhancement in
ortic wall thickening after 1-year of treatment, devoid of contrast
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Clinical and Biochemical Findings at Diagnosis and
Treatment Data of the Investigated GCA Cohort of 35 Patients
Age, median (range) years 80 years (57–92)
Gender, male/female, no. 10/25
Clinical data at diagnosis:
Duration of symptoms,
median (range) days
30 (5–365)
Cranial symptoms (%) 74.3
Headache 60
Scalp tenderness 43
Jaw claudication 48.6
Ocular events 31.4
Stroke 5.7
Systemic symptoms (%) 65.7
Fever 14.3
Weight loss 37.1
Polymyalgia rheumatica (%) 28.6
Extremity claudication (%) 0
Relapse during 1-year
follow-up (%)
5
Treatment:
Aspirin (%) 65.7
Statin (%) 40
ACEI/ARB (%) 60
Glucocorticoids:
Bolus of methylprednisolone
at diagnosis (n8)
6
Time to <10mg/day during
follow-up (days)
215 61
Cumulated prednisone dose
at the second CTA
assessment (mg)
6271 776
Laboratory findings at diagnosis and at new CTA assessment:
ESR, mm/hour 92 34 13 7
CRP, mg/dl 10.6 7.7 0.5 0.5
Hemoglobin, mg/dl 115 18 135 10
Haptoglobin, mg/dl 3.9 1.3 1.5 0.5

Values are the meanSD unless otherwise indicated.
ACEI¼ angiotensin converter enzyme inhibitors, ARB¼ angiotensin
II receptor blockers, CRP¼C-reactive protein, ESR¼ erythrocyte sedi-
Treatment-Induced Changes in CT-Angiography Findings of LVVPatients with 3 or 4 of these items were considered to have a
strong SIR, whereas patients with2 were considered to have a
weak SIR.
CTA Protocol
CTAwas performed using a multi-slice CT scanner (Soma-
tom Definition Flash, Siemens Medical Solutions, Erlangen,
Germany) with the following scanning conditions: collimation
0.6mm, 120 kV, mAs determined by automatic modulation
dose, and reconstruction slice thickness of 5.0 and 1mm. One
hundred milliliter of non-ionic contrast agent (370mg I/ml)
was injected through the ante-cubital vein using a power
injector at the rate of 4ml/s. Early arterial and late venous phases
were acquired. We used the bolus-tracking method at the des-
cending aorta level and set 100 Hounsfield units (HU) as the
triggering threshold for the arterial phase. The venous phase scan
was taken 60 seconds after the arterial phase was completed.
Significant enhancement of the aortic wall was considered when
an increase of 20 HU or more existed between the arterial and
venous phases.
Vascular dilatation or stenosis, as well as vessel wall
thickening, were assessed at 4 aortic segments (ascending
thoracic aorta, aortic arch, descending thoracic aorta and
abdominal aorta) in all patients. Moreover, in 16 patients, the
presence of significant wall thickening and appropriate and
timely imaging acquisition permitted evaluation of contrast
enhancement of the aortic wall at both assessments. As in
the first evaluation,4 aortitis was defined as circumferential
aortic wall thicknening 2mm observed in zones without
adjacent atheroma. In addition, in the present study, contrast
enhancement was evaluated, when feasible, in both CTA assess-
ments, in order to distinguish between inflammatory activity
(presence of contrast enhancement) and vascular remodeling
(absence) (Figure 1).4,27–29 Aortic dilatation was defined by a
diameter >4 cm in the ascending aorta, 4 cm in the rest of the
thoracic aorta, and 3 cm in the abdominal aorta. Loss of the
physiologically progressive diameter reduction of the aorta was
also considered dilatation.18,30,31
The aortic tributaries, including brachiocephalic trunk,
carotid, subclavian, axillary, splanchnic (celiac and mesenteric),
renal, iliac, and femoral arteries, were also evaluated. Radio-
logical findings of large-vessel inflammation were circumfer-
ential wall thickness >1mm and contrast enhancement of the
artery wall. Signs of abnormal large-vessel remodeling were
arterial dilatation, and the presence of focal stenoses not related
to atheroma.4
CTA evaluation was performed by the same radiologists
(PA and JGC), blinded to the clinical and laboratory data.
Statistical Analysis
Mann–Whitney U test and Student’s t test, for paired or
independent data when applicable, were used for quantitative
data. Fisher’s exact test was applied to contingency tables for
qualitative data. Bonferroni correction was applied to multiple
comparisons. Calculations were performed with the IBM SPSS
Statistics (Version 20.0, Armonk, NY).
RESULTS
Medicine  Volume 94, Number 5, February 2015Clinical and Laboratory Findings
Of the 35 patients finally included, 25 were women and 10
men with a mean age of 79 6 years (meanSD). Median
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.follow-up time between both radiologic evaluations was 13.5
months (IQ25–75% 12.4–15.8).
Although two patients relapsed during the study period,
at the time of the second CTA, all patients were in
clinical remission and receiving glucocorticoid treatment,
with a median prednisone dose of 5mg/day (ranging from
10mg/day, due to a recent relapse, to 2.5mg/day). No specific
symptoms or signs of large-vessel stenosis (bruits, asymmetry
in arm blood pressure or extremity claudication) were referred
or detected. The main clinical, laboratory and treatment data of
the study cohort are summarized in Table 1.
Prevalence and Topography of Large-Vessel
Involvement After 1-Year Follow-Up
mentation rate. Ocular events include diplopia and amaurosis due to
anterior ischemic optic neuropathy.Nineteen out of the 35 patients (54.3%) had abnormal CTA
findings. Radiological signs suggesting LVV (wall thickening)
were still seen in 17 patients (48.5%) and aortic dilation in 5
www.md-journal.com | 3
TABLE 2. Topography of Inflammatory Large-Vessel Involvement in the Study Cohort at the Time of Diagnosis and at the Follow-
Up Evaluation
At Diagnosis Follow-Up
Vascular Territory Involved Number of Patients (%) Number of Patients (%)
LVV 25 (71.4%) 17 (48.6%)
Aorta 24 (68.6%) 16 (45.7%)
Thoracic aorta 24 (68.6%) 15 (42.9%)
Ascending aorta 10 (28.6%) 4 (11.4%)
Aortic arch 19 (54.3%) 11 (31.4%)
Descending aorta 21 (60%) 13 (37.1%)
Abdominal aorta 16 (45.7%) 9 (25.7%)
Panaortitis 8 (22.8%) 3 (8.6%)
Primary and secondary aortic branches 19 (54.3%) 12 (34.2%)
Brachiocephalic trunk 16 (45.7%) 9 (25.7%)
Carotid arteries 11 (31.4%) 4 (11.4%)
Subclavian arteries 14 (40%) 5 (14.2%)
Axillary arteries 7 (20%) 4 (11.4%)
Splanchnic territory 7 (20%) 4 (11.4%)
Renal arteries 1 (2.8%) 1 (2.8%)
Iliac arteries 6 (17.1%) 2 (5.7%)
Femoral arteries 9 (25.7%) 5 (14.2%)
gme
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and the aortic arch were the most affected segments: aortic
thickening was observed in 13 (37.1%) of patients at the
descending thoracic aorta and in 11 (31.4%) of patients at
the aortic arch, followed by the abdominal aorta and the
ascending aorta, that were involved in 9 (25.7%) and in 4
(11.4%) of patients, respectively. Furthermore, CTA-defined
aortic branch inflammation was still detected in 12 (34.2%)
patients. Detailed frequencies of radiological LVV at the differ-
ent vascular segments evaluated and its distribution in the aorta
at both evaluation times are summarized in Table 2 and
Figure 2, respectively. Topography of the aortic segments with
persistence, reduction or resolved radiological inflammation is
depicted in Figure 2.
When comparing both evaluations, initial and present,
vessel wall thickening was still present in 17 (68%) of the
25 patients who initially had this finding. A significant
reduction in the mean aortic wall thickness was detected in
all aortic segments (Table 3). Moreover, the number of vascular
segments affected substantially decreased and none of the 35
patients developed new inflammatory lesions in previously
unaffected areas (Figure 2). Post-hoc evaluation of the 16
patients in whom contrast enhancement assessment was feas-
ible, disclosed that all patients but 1 (93.75%) had contrast
enhancement of the aortic wall as a sign of active vasculitis27–29
in the first CTA evaluation performed at the time of GCA
diagnosis. Conversely, at the second assessment, contrast
enhancement was evident in the aortic wall in only one
(6.25%) of the 16 evaluable patients (see Figure 3).
There were no significant differences in aortic diameters
when comparing both evaluations. No new aortic dilatation was
detected and, moreover, dilatation detected at the ascending
thoracic aorta in 5 patients at the time of GCA diagnosis,
LVV¼ large-vessel vasculitis (any vessel), Panaortitis¼ all aortic seremained stable. At the first assessment, only one patient
showed a vascular stenosis, concomitant with wall thickening,
located in the left renal artery. At the second assessment, these
4 | www.md-journal.comremained stable and another patient developed a new vascular
stenosis in a segment located at the inferior mesenteric artery
with no previously apparent CTA inflammatory signs.
Clinical, Laboratory and Treatment Features
Associated With Persistence or Resolution of CTA
Signs of Large-Vessel Inflammation
Twenty-five out of the 35 patients who completed both
evaluations had signs of LVV at the time of diagnosis. Of those,
17 had persisting signs of LVV at follow-up whereas vessel wall
thickening had resolved in the remaining 8. The time lapse
between both CTA assessments was similar in patients with or
without persisting LVV at follow-up. No significant differences
in age, gender or clinical symptoms were found between both
groups (Table 4). Only 2 patients suffered from relapse, 1 in
each group.
Acute phase reactants at the specified time-points during
follow-up in patients with or without persisting signs of LVV at
the second CTA are shown in Figure 4. Only hemoglobin was
significantly lower at the first follow-up visits in patients with
persisting vessel wall thickening. When comparing acute phase
reactants in patients in whom wall thickening persisted
unchanged versus those who experienced improvement, only
ESR was significantly higher in patients with unmodified wall
thickening. No relationship was found between the presence of
a strong or weak SIR at diagnosis and the outcome of the
imaging abnormalities during follow-up (Table 4).
Data regarding patients’ therapy are summarized in
Table 4 and Figure 5. There were no significant differences
in the percentage of patients who had received IV methyl-
prednisolone megadoses at diagnosis because of cranial
ischemic manifestations, or other medications including aspirin,
nts affected.statins, or angiotensin-converting enzyme inhibitors /angioten-
sin II receptor blockers between both groups. There were no
differences either in the time required to achieve a maintenance
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
At diagnosis At one -year follow-up
Pat ATA Ao Arch DTA AA ATA Ao Arch DTA AA
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Wall thickeing Reduction in wall thickening No thickening
co
tic.
Medicine  Volume 94, Number 5, February 2015 Treatment-Induced Changes in CT-Angiography Findings of LVVFIGURE 2. Distribution of the aortic wall thickening in the GCA
DTA¼descending thoracic aorta; AA¼ abdominal aorta; Ao¼ aorprednisone dose below 10mg/day, in the cumulated prednisone
dose at the second imaging between patients with persisting or
TABLE 3. Aortic Wall Thickness at Diagnosis and at the follow-
Up Assessment
At diagnosis At follow-up P

Aortic wall thickness (mm)y
Ascending thoracic aorta 1.51 0.81 1.22 0.59 0.018
Aortic arch 2.31 1.02 1.77 0.87 0.002
Descending thoracic aorta 2.74 1.06 2.02 0.95 <0.001
Abdominal aorta 1.68 0.86 1.31 0.58 0.012

statistical analysis performed with paired data.
yValues are meanSD.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.resolved vessel wall thickening or in the prednisone doses at the
different follow-up visits.
DISCUSSION
Recent prospective studies have revealed an elevated
prevalence of inflammation of the aorta and its primary and
secondary branches in GCA.4–13 However, the clinical impact
of large-vessel inflammation detected at diagnosis on patient’s
outcome is unclear. Population-based studies have demon-
strated an increased incidence of thoracic aortic aneurysm in
GCA.14,15,17,32 However, a direct link between aortic inflam-
mation and later development of aortic dilatation seems reason-
able but it has not been clearly established. Male gender,
smoking habit, and hypertension have been associated with
higher risk of aortic aneurysm in patients with GCA in some
hort at both CTA assessments. ATA¼ ascending thoracic aorta;studies.17,18,33 Blockmans et al demonstrated, indeed, larger
aortic diameters detected by computed tomography (CT) in a
heterogeneous cohort of GCA patients who had increased aortic
www.md-journal.com | 5
TABLE 4. Clinical Features at Baseline and Treatments Received by Patients With Persisting or Resolved Large-Vessel Thickening at
the Second CTA Evaluation
Persisting LVV
Yes (17 Patients) No (8 Patients) P
Age (years)

78 8 81 5 0.272
Gender, male/female, N. 4/13 3/5 0.640
Duration of follow-up (days)

509 130 460 73 0.297
Cranial symptoms (%) 59 87 0.205
Headache (%) 47 87 0.088
Scalp tenderness (%) 29 50 0.394
Jaw claudication (%) 41 62 0.411
Ischemic events (%) 35 25 0.956
Systemic symptoms (%) 82 50 0.156
Fever (%) 23 12 0.156
Weight loss (%) 64 12 0.030þ
Extremity claudication (%) 0 0
Strong systemic inflammatory response# (%) 87.5 58.8 0.166
Treatment
Aspirin (%) 53 75 0.402
Statin (%) 23.5 50 0.359
ACEI/ARB (%) 23 50 0.186
IV methylprednisolone mega-doses at diagnosis (%) 11 0 0.825
Cumulated prednisone dose (mg) at the second assessment

6494 959 5984 575 0.196
Time (weeks) required to achieve a maintenance prednisone dose < 10mg/day

212 56 179 44 0.161

Values are meanSD. ACEI¼ angiotensin converting enzyme inhibitors, ARB¼ angiotensin II receptor blockers.
þ Statistical significance was lost after Bonferroni correction.
# Defined as the presence of at least 3 of the following items: fever>37 8C, weigh loss>3 kg, hemoglobin<11 g/L, erythrocyte sedimentation rate
85mm/h.
At diagnosis At one-year follow-up
Pacient TA AA TA AA
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Wall thickening with contrast enhancement      
Wall thickening without contrast enhancement
No wall thickening
TA = thoracic aorta; AA = abdominal aorta.    
FIGURE 3. Distribution of the contrast enhancement in the followed GCA cohort at both radiologic assessments. TA¼ thoracic aorta;
AA¼ abdominal aorta.
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Moreover, although there are reports of symptomatic stenoses
of primary and secondary branches of the aorta leading to
extremity claudication,35,36 mesenteric ischemia,37,38 myo-
cardial infarction,39 or ischemic stroke,40,41 the percentage
of patients who develop large-vessel stenosis is unknown and
the relationship between stenosis and previous inflammatory
involvement has not been demonstrated. It is estimated that
between 5% and 15% of patients have signs or symptoms
derived from large-vessel stenosis at diagnosis or during
follow-up.32,35,42,43 However, since studies addressing this
point are retrospective and not all patients were imaged, it is
difficult to distinguish between signs and symptoms derived
form atherosclerotic vascular disease, which is not unusual in
the age group targeted by GCA, from those derived from
vasculitic involvement.
To date, prospective longitudinal studies in unselected
cohorts of GCA patients in order to define the outcome of
large-vessel inflammation have not been reported. This is the
first study prospectively evaluating the early outcome of CTA
defined large-vessel vasculitis detected at the time of diagnosis
in a cohort of patients with biopsy-proven GCA subjected to a
standardized glucocorticoid treatment in accordance with inter-
national recommendations.44 We evaluated both the outcome of
vessel wall thickening suggestive of vasculitis as well as
changes in the vessel diameter indicating dilatation or stenosis
after approximately 1 year of follow-up.
Unexpectedly, given the complete clinical response to
treatment in the majority of patients, persistent vessel wall
thickening was found in 48.5% of patients, two-third of the
patients who had signs of LVV at the time of diagnosis.
However, vessel wall thickening as well as the number of
FIGURE 4. Acute phase reactants at scheduled time points during 1
assessment.affected vessels significantly decreased and there was no
new involvement of previously spared segments, indicating,
to a certain extent, a substantial response of large-vessel
FIGURE 5. Cumulated prednisone dose (A) and daily prednisone do
persisting or resolved LVV.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.inflammation to glucocorticoid therapy. Moreover, it has been
repeatedly remarked that the capacity of imaging techniques to
detect signs of large-vessel inflammation quickly decreases
after gluococorticoid treatment.45–48 The significance of per-
sistent vessel wall thickening during glucocorticoid treatment is
unclear. It may represent persistent subclinical, pauci-sympto-
matic vascular inflammation, refractory to maintenance gluco-
corticoid therapy, which would strongly underline the need for
more efficient therapies able to abrogate silent large-vessel
inflammation.49 However, it is noteworthy that patients were
in clinical remission with normal or close to normal acute phase
reactants at the time of the second assessment. Moreover, no
major differences in serum concentrations of acute phase
reactants over time was observed between patients with
resolved large-vessel involvement and those with persisting
vascular thickening. Therefore, major persistence of inflamma-
tory activity was unlikely.
Second temporal artery biopsies have been performed to
some patients with GCA several months or years after the
initiation of glucocorticosteroid treatment for a variety of
reasons: including confirmation of a clinically based diagnosis,
necropsy, or as part of an ancillary study in the context of an
international multicentre clinical trial.50–53 In these specimens,
scattered small foci of inflammatory cells persist but the more
striking finding consists of prominent medial fibrosis and
vascular wall remodeling. It is likely that persistent vascular
wall thickening primarily represents fibrosis and vascular remo-
deling rather than major persistence of active inflammation.
This is supported by the observation of contrast enhancement in
only one out of 16 patients in whom this finding could be
assessed. Concomitant PET scan may have been useful to
differentiate active inflammation and scarring in patients with
r follow-up of patients with or without persisting LVVat the secondpersisting vascular thickening as recently suggested for patients
with cardiac involvement by eosinophilic granulomatosis with
polyangiitis.12,54
se (B) at scheduled time points during follow-up in patients with
www.md-journal.com | 7
No changes in aortic diameter indicative of dilatation were
observed when comparing the initial and the follow-up assess-
ments. This observation supports the concept that aortic dilata-
tion is a delayed complication as suggested by retrospective,
population-based studies14,15,17,32 and a cross-sectional study
with its long-term follow-up.18,19
Regarding to vascular stenosis, only 1 patient developed
reduction in the inferior mesenteric artery diameter and no
patients had clinical signs or symptoms related to vascular
stenosis in the second assessment indicating that the develop-
ment of stenosis in the primary or secondary branches of the
aorta is infrequent in the early outcome of unselected patients
with GCA. Given the imaging modality used (CTA), con-
clusions about stenosis in more distal territories such as infra-
popliteal arteries, which may be involved by GCA,3,9,55–58
cannot be drawn. These data underlines important differences
with Takayasu disease. Based on the observation that GCA
frequently targets large vessels, it has been recently proposed
that GCA and Takayasu disease may be the edges of the
spectrum of a single disorder and that clinico-pathological
differences may be related to ageing of the immune and/or
vascular system.59 Although in the absence of an identified
etiology discussing whether or not Takayasu and GCA are
different conditions or the same disease may be inconclusive,
our observations support that there are important differences in
vascular remodelling between both conditions. While patients
with Takayasu disease frequently and typically develop vas-
cular stenoses, sometimes in spite of immunosuppressive
therapy, vascular lumen reduction is unusual in unselected
patients with GCA.
Our study has the strengths of its prospective nature and
careful imaging analysis of the vascular territories accessible to
CTA. It has also some limitations including the relatively small
size of the patient cohort and the short-term follow-up.
Extended studies are necessary to delimitate the long-term
outcome and clinical impact of large-vessel inflammation
in GCA.
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